SCHEMBL2874758

SCHEMBL2874758

COc1cccc(CC(=O)O)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.56
ALOX5 P09917 1/20 0.54
PTGS2 P35354 1/20 0.54
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 2/20 0.52
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
ALOX12 P18054 1/20 0.52
MAPK1 P28482 1/20 0.52
CALM1 P0DP23 1/20 0.51
GAA P10253 4/20 0.50
AKR1B1 P15121 1/20 0.50
ANO1 Q5XXA6 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11132561 0.89 HTT (0.51) IDO1ALOX5PTGS2HSD17B10LMNA
SCHEMBL28235226 0.86 IDO1 (0.60) IDO1ALOX5PTGS2ALDH1A1HSD17B10
Syringol SCHEMBL28068397 0.84 CXCL8 (0.57) IDO1ALOX5PTGS2ALDH1A1HSD17B10
SCHEMBL29431297 0.83 HSD17B10 (0.61) HSD17B10LMNAMAPTAKR1B1TSHR
SCHEMBL155982 0.83 HSD17B10 (0.61) HSD17B10LMNAMAPTAKR1B1TSHR
SCHEMBL3691207 0.83 ALOX5 (0.59) IDO1ALOX5PTGS2ALDH1A1HSD17B10
SCHEMBL28840672 0.83 ALOX5 (0.55) IDO1ALOX5PTGS2ALDH1A1HSD17B10
SCHEMBL5120093 0.83 L3MBTL1 (0.53) KDM4EMAPTAKR1B1TSHRTDP1
SCHEMBL2310865 0.82 STING1 (0.54) ALDH1A1HSD17B10LMNAKDM4EMAPT
SCHEMBL991380 0.82 KMT2A (0.54) ALDH1A1HSD17B10KDM4EHPGDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461384-B2 Preparation of amides from an acid and amine for intermediates in the synthesis of morphinans MALLINCKRODT LLC (US) 2013-06-11 US disclosed
US-8445682-B2 Preparation of 3,4-dihydroisoquinolines from an acid and an amine MALLINCKRODT LLC (US) 2013-05-21 US disclosed
US-8232400-B2 Preparation of 3,4-dihydroisoquinolines in the synthesis of morphinans MALLINCKRODT LLC (US) 2012-07-31 US disclosed
EP-2177504-A1 Preparation of amides from an acid and amine for intermediates in the synthesis of morphinans Mallinckrodt Inc. (US) 2010-04-21 EP disclosed
US-20100063290-A1 Preparation of 3,4-Dihydroisoquinolines from an Acid and an Amine MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) 2010-03-11 US disclosed
EP-2161253-A2 Process for the preparation of 3,4-dihydroisoquinolines in the synthesis of morphinans Mallinckrodt Inc. (US) 2010-03-10 EP disclosed
US-20090247760-A1 Preparation of Amides from an Acid and Amine for Intermediates in the Synthesis of Morphinans MALLINCKRODT INC. (US) 2009-10-01 US disclosed
US-20090247761-A1 Preparation of 3,4-Dihydroisoquinolines in the Synthesis of Morphinans MALLINCKRODT INC. (US) 2009-10-01 US disclosed
EP-2099745-A2 PREPARATION OF 3,4-DIHYDROISOQUINOLINES FROM AN ACID AND AN AMINE Mallinckrodt Inc. (US) 2009-09-16 EP disclosed
WO-2008073390-A2 PREPARATION OF 3,4-DIHYDROISOQUINOLINES FROM AN ACID AND AN AMINE MALLINCKRODT INC. (US) 2008-06-19 WO disclosed
US-20080051418-A1 Arylalkanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-28 US disclosed
EP-1829863-A1 ARYLALKANOIC ACID DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-09-05 EP disclosed
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247761-A1 Preparation of 3,4-Dihydroisoquinolines in the Synthesis of Morphinans PNN, CDKL3, ORAI3 IDO1 430/4885ALOX5 611/4885PTGS2 3369/4885
US-20100063290-A1 Preparation of 3,4-Dihydroisoquinolines from an Acid and an Amine PNN, AOX1, PAM IDO1 487/4885ALOX5 349/4885PTGS2 3302/4885
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 IDO1 660/4885ALOX5 1513/4885PTGS2 4593/4885
US-20080051418-A1 Arylalkanoic Acid Derivative INSR, NPY1R, GPR119 IDO1 1352/4885ALOX5 672/4885PTGS2 4502/4885
US-20090247760-A1 Preparation of Amides from an Acid and Amine for Intermediates in the Synthesis of Morphinans PNN, PAM, NPM1 IDO1 334/4885ALOX5 312/4885PTGS2 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.